PharmaMar presents new results for lurbinectedin at ASCO Genitourinary Cancers symposium

PharmaMar (MSE:PHM) has presented at the ASCO Genitourinary Cancers symposium that has been held from the 25th to 27th of January in San Francisco, USA, two abstracts with Zepzelca® (lurbinectedin) in Prostatic Small Cell and Neuroendocrine Carcinoma (SC/NEPC), and Metastatic Neuroendocrine Carcinomas of the genitourinary tract. The poster presented by Dr. Haley M. Meyer et al., from Mayo Clinic Arizona is titled “Lurbinectedin in Prostatic Small Cell and Neuroendocrine Carcinoma”. SC/NEPC is a high-grade, invasive malignancy that is distinct to Prostatic Adenocarcinoma and behaves similarly to Small Cell Lung Cancer (SCLC), and treatments in second-line and beyond are major clinical challenges. This study was carried out in four academic centers of eighteen highly pretreated metastatic patients with a median number of four prior systemic therapies administered before lurbinectedin. Clinical Benefit Rate was found in 56.3%, with Partial Response in 5 of 16 patients, 31%. The study concluded that lurbinectedin is a well-tolerated and active treatment option for patients with SC/NEPC. Dr. Alan H. Bryce, M.D., C.P.E., Chief Clinical Officer of City of Hope® Cancer Center, Phoenix, commented “the Partial Response rate of 31% and Stable Disease in an additional 25% is quite promising in this highly refractory disease population”. Dr. Mohammad Jad Moussa from The University of Texas, MD Anderson Cancer Center, Houston, Texas, presented the poster “Clinical efficacy of lurbinectedin in Metastatic Neuroendocrine Carcinomas of the genitourinary tract: Multi-institutional real-world experience.” Neuroendocrine Carcinomas (NEC) of the genitourinary (GU) tract, including Small Cell (SC) metastasic NEC (mNEC) and Large Cell (LC) NEC, are rare aggressive malignancies. The investigator reports the first multi-institutional data with fourteen patients treated with lurbinectedin in GU mNEC with encouraging responses close to those seen in SCLC, in previously treated bladder mNEC. Larger cohorts are needed to confirm the survival benefit and genetic analyses are warranted to identify characteristics of responders; the author concludes. Highlighted studies at ASCO Gu 2024 PRODUCTTITLELEAD AUTHORABSTRACT Zepzelca® (lurbinectedin)Lurbinectedin in Prostatic Small Cell and Neuroendocrine CarcinomaHaley M. MeyerABSTRACT: 164 SESSION TYPE: Prostate Cancer POSTER: G14 DATE: January 25, 2024 11:30 – 13 :00 GMT-8 Clinical efficacy of lurbinectedin in Metastatic Neuroendocrine Carcinomas of the genitourinary tract: Multi-institutional real-world experience.Mohammad Jad Moussa CousinABSTRACT: 601 SESSION TYPE: Urothelial Carcinoma POSTER: G7 DATE: January 26, 2024 11:30 – 13:00 GMT-8

The release as fetched from its publisher. pharmamar.com ↗